Glenmark gets USFDA nod for generic Prograf capsules

Prograf capsules, 0.5 mg, 1 mg and 5 mg market achieved annual sales of approximately US$ 286.8 million.

48
USFDA
Picture: Pixabay

Last Updated on November 11, 2020 by The Health Master

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (FDA) for tacrolimus capsules USP, 0.5 mg, 1 mg and 5 mg, the generic version of Prograf capsules, 0.5 mg, 1 mg and 5 mg, of Astellas Pharm US, Inc.

According to IQVIA sales data for the 12 month period ending September 2020, the Prograf capsules, 0.5 mg, 1 mg and 5 mg market achieved annual sales of approximately US$ 286.8 million.

Glenmark’s current portfolio consists of 166 products authorized for distribution in the US market place and 45 ANDA’s pending approval with the USFDA.

In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.


The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.